223 related articles for article (PubMed ID: 34083693)
21. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
22. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
Wu X; Qi J; Bradner JE; Xiao G; Chen LF
J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
[TBL] [Abstract][Full Text] [Related]
23. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
Guerrero-Martínez JA; Reyes JC
Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
[TBL] [Abstract][Full Text] [Related]
24. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
25. High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma: a pooled analysis.
Zhu Y; Zhou C; He Q
J Int Med Res; 2019 Jan; 47(1):383-390. PubMed ID: 30394818
[TBL] [Abstract][Full Text] [Related]
26. Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma.
He F; Li J; Xu J; Zhang S; Xu Y; Zhao W; Yin Z; Wang X
J Exp Clin Cancer Res; 2015 May; 34(1):47. PubMed ID: 25975202
[TBL] [Abstract][Full Text] [Related]
27. miR-22 targets YWHAZ to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival.
Chen M; Hu W; Xiong CL; Qu Z; Yin CQ; Wang YH; Luo CL; Guan Q; Yuan CH; Wang FB
Oncotarget; 2016 Dec; 7(49):80751-80764. PubMed ID: 27811373
[TBL] [Abstract][Full Text] [Related]
28. Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma.
Sun C; Huang S; Wang H; Xie R; Zhang L; Zhou Q; He X; Ju W
Mol Carcinog; 2019 Dec; 58(12):2266-2275. PubMed ID: 31523845
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma.
Duan X; Li W; Hu P; Jiang B; Yang J; Zhou L; Mao X; Tian B
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33078826
[TBL] [Abstract][Full Text] [Related]
30. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma.
Wang SM; Ooi LL; Hui KM
Clin Cancer Res; 2011 Sep; 17(18):6040-51. PubMed ID: 21825042
[TBL] [Abstract][Full Text] [Related]
32. KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma.
Shi L; Zhang W; Zou F; Mei L; Wu G; Teng Y
BMC Cancer; 2016 Oct; 16(1):815. PubMed ID: 27769251
[TBL] [Abstract][Full Text] [Related]
33. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
34. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
Zhou X; Sun T; Meng Y; Luo J; Chen J; Xia B; Zhang Z; Cheng Z; Wang X
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760217
[TBL] [Abstract][Full Text] [Related]
35. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
36. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
37. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1.
Liu Y; Ding Y; Huang J; Wang S; Ni W; Guan J; Li Q; Zhang Y; Ding Y; Chen B; Chen L
PLoS One; 2014; 9(2):e88393. PubMed ID: 24551096
[TBL] [Abstract][Full Text] [Related]
38. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression.
Chen H; Hu L; Luo Z; Zhang J; Zhang C; Qiu B; Dong L; Tan Y; Ding J; Tang S; Shen F; Li Z; Wang H
Mol Cancer; 2015 Nov; 14():186. PubMed ID: 26538215
[TBL] [Abstract][Full Text] [Related]
39. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
40. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
